
Stephen Chia
Advertisement
Articles by Stephen Chia


21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial
ByGabriel N. Hortobagyi, MD, FACP,Daniil Stroyakovskiy,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,John Crown,Aditya Bardia, MD, MPH, FASCO,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Sherene Loi, MD, PhD,Binghe Xu,Sara A. Hurvitz, MD,Carlos Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Frances Visco,Federico Parnizari,Farhat Ghaznawi,Zheng Li,Sorcha Waters,Arunava Chakravartty,Dennis J. Slamon, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma
2
Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer
3
NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium
4
Liquid Biopsies, Blood-Based MCED Tests for Detecting CRC in Young Patients
5


